Stockscreener 앱 받기
0.4585
6.56%
-0.0322
시간 외 거래:
.49
0.0315
+6.87%
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics announces cGMP production success - Investing.com
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - BioSpace
Lineage Cell Therapeutics announces cGMP production success By Investing.com - Investing.com Nigeria
BlackRock, Inc.'s Strategic Acquisition of Lineage Cell Therapeu - GuruFocus
LCTX (Lineage Cell Therapeutics Inc) has impressive results - uspostnews.com
Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday - Defense World
JPMorgan Chase & Co. Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Upward Trajectory: Lineage Cell Therapeutics Inc (LCTX) Posts a Gaine, Closing at 0.47 - DWinneX
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Renaissance Technologies LLC - Defense World
Lineage Cell Therapeutics Inc Inc. (LCTX) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com
Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com
LCTX’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3 - Business Wire
Market Recap: Lineage Cell Therapeutics Inc (LCTX)’s Negative Momentum, Closing at 0.41 - DWinneX
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the - GuruFocus
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire
Revolutionary Eye Drug Delivery Methods: Lineage CEO Joins Elite Panel at Major Ophthalmology Conference - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
BioTime, Inc. : CORRECTION - MarketScreener
BioTime, Inc. : BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments - marketscreener.com
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
Let’s Dive Into The Lineage Cell Therapeutics Inc (AMEX: LCTX) Stock Forecast. - Marketing Sentinel
LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Weak Fundamental Momentum Sinks Lineage Cell Therapeutics Inc - Marketing Sentinel
LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com
Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener
Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com
It’s Worth A Gamble To Have A Position In Lineage Cell Therapeutics Inc (AMEX: LCTX) At $0.50. - Marketing Sentinel
LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics Inc (AMEX: LCTX) Shares Declined By -27.01% In One Month. - Marketing Sentinel
B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World
B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks
B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com
HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World
Now Is The Time To Build A Position In Lineage Cell Therapeutics Inc (AMEX:LCTX) - Marketing Sentinel
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World
Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia
Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks
Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga
Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India
Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa
0.39%
3.66%
자본화:
|
볼륨(24시간):